Mylab on Tuesday announced that the National TB Elimination Program has incorporated Mylab’s PathoDetect MTB RIF and INH Resistance Detection Kit to further its effort to eliminate TB by 2025.
According to a press statement, the test is now integrated into the Ni-kshay portal, amplifying the nation’s capabilities in the fight against tuberculosis.
“The inclusion of the PathoDetectTM kit in the National TB Elimination Program marks a pivotal moment in India’s commitment to combating tuberculosis, a disease that continues to pose a significant public health challenge,” the company said in a statement.
This manual-intervention-free test, designed for the rapid and accurate detection of multidrug-resistant TB, offers advanced capabilities for identifying TB and resistance to Rifampicin (RIF) and Isoniazid (INH), two critical first-line drugs in TB treatment, the company claimed.
“We are honoured to contribute to our Prime Minister’s visionary initiative to eradicate TB. The availability of MTB on the Ni-kshay platform represents a milestone in India’s fight against TB. As India takes a giant leap forward in its fight against TB, this diagnostic solution will make a substantial impact on the efficiency and effectiveness of TB control measures. It will prove beneficial for the State authorities to report the TB cases,” Hasmukh Rawal, MD & Co-founder, Mylab Discovery Solutions said.
The government has included the indigenous latent TB test, Cy-TB, in NTEP, as well as the MTB RIF & INH Resistance Detection Kit into NTEP, along with an AI-enabled portable X-ray device for TB screening in the national programme.
